Farco-Pharma

Focus: Farco-Pharma is a Germany-based medical device company specializing in lubricants, catheter inflation systems, and instillation therapy products. The company operates in a niche segment of the medical device market with a focused product portfolio.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Farco-Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Farco-Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Oxybutynin Hydrochloride

Spina Bifida

Phase 3

Clinical Trials (1)

NCT07027020Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction

Phase 3

Help build intelligence for Farco-Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to Phase 3 development of Oxybutynin Hydrochloride for Spina Bifida, a rare disease affecting a vulnerable population
Medical device expertise in specialized categories (catheters, lubricants) represents differentiated domain knowledge in underserved clinical areas
European headquarters in Cologne provides potential exposure to EU regulatory pathways and global market expansion

Watch Out For

Minimal hiring activity (zero open roles) suggests limited near-term career mobility or expansion within the organization
Limited pipeline visibility with only one Phase 3 program and no public financial data constrains understanding of company stability and R&D investment capacity
No published research output and sparse public information raise questions about scientific visibility and competitive positioning in the market

Generated by Claude from Farco-Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo